Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Löst diese riesige Entdeckung die Kupferkrise der KI? So ändert sich die Rechnung durch diesen Explorer!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JTC1 | ISIN: GB00B7KR2P84 | Ticker-Symbol: EJT1
Xetra
15.01.25
10:15 Uhr
5,930 Euro
+0,100
+1,72 %
1-Jahres-Chart
EASYJET PLC Chart 1 Jahr
5-Tage-Chart
EASYJET PLC 5-Tage-Chart
RealtimeGeldBriefZeit
5,9005,91413:02
5,9005,91413:02
Dow Jones News
247 Leser
Artikel bewerten:
(1)

easyJet plc: Notice of AGM

Finanznachrichten News

DJ Notice of AGM

easyJet plc (EZJ) 
Notice of AGM 
13-Jan-2025 / 10:33 GMT/BST 
=---------------------------------------------------------------------------------------------------------------------- 
13 January 2025 
easyJet plc 
(the "Company") 
 
Notice of Annual General Meeting 
 
The Company confirms that the following documents are being made available to shareholders today: 
   -- Notice of Annual General Meeting ("AGM Notice"); and 
   -- Form of Proxy for Annual General Meeting. 
In accordance with UK Listing Rule 6.4.1 copies of the above documents have been submitted to the National Storage 
Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism. The 
AGM Notice is also available on the Company's website at https://corporate.easyjet.com/investors/shareholder-services/ 
shareholder-meetings/. 
The 2024 Annual Report and Accounts continue to be available on the Company's website: https://corporate.easyjet.com/ 
investors/reports-and-presentations/. 
Annual General Meeting Arrangements 
The AGM will take place on Thursday, 13 February 2025 at 10.00 a.m. at Hangar 89, London Luton Airport, Luton, LU2 9PF. 
 Shareholders are welcome to attend and vote at the AGM in person. The Company is also pleased to be able to offer 
facilities for shareholders to attend and vote at the AGM electronically should they wish to do so. Detailed 
information on how to join the meeting are set out in the AGM Notice. If you are unable to attend in person, the Board 
strongly encourage shareholders to vote on the resolutions prior to the meeting by completing an online proxy 
appointment form appointing the Chair of the meeting as their proxy, further details of which are included in the AGM 
Notice. 
 
Any changes to the AGM arrangements will be published on the Company's website (https://corporate.easyjet.com) and 
announced through the London Stock Exchange. Shareholders should therefore continue to monitor the website for any 
announcements and updates. 
 
Shareholders are urged to submit their votes by proxy before 10.00 a.m. on Tuesday, 11 February 2025. 
 
Disenfranchisement 
As shareholders will be aware, to ensure that the Company complies with European ownership and control requirements the 
Board continues to exercise its powers in accordance with easyJet's articles of association to suspend voting rights in 
respect of certain shares ('Affected Shares') held by UK and other non-EU nationals so that a majority of the voting 
rights in easyJet are held by EU persons. For the period of such suspension, the relevant shareholders would not be 
entitled to attend, speak or vote at shareholder meetings, including the AGM, in respect of the shares subject to the 
suspension. Further information can be found on easyJet's website at: https://corporate.easyjet.com/investors/ 
shareholder-services/eu-share-ownership. 
 
As at 13 January 2025, the level of ownership by EU persons was 37.27%. Accordingly, easyJet has suspended voting 
rights in respect of certain shares ('Affected Shares') held by Relevant Persons in accordance with easyJet's articles 
of association so that a majority of the voting rights in easyJet are held by EU Persons. 
 
Shareholders who own shares whose voting rights will be suspended (and therefore whose votes will not be counted) at 
the AGM will receive a notice (an "Affected Share Notice") by post from Equiniti, our Registrars, on or around 4 
February 2025 notifying them of the suspension of voting rights in respect of their Affected Shares. 
 
We would recommend that all shareholders vote in advance of the AGM, even in respect of any Affected Shares that they 
may hold. This is because those shares may be re-enfranchised in advance of the AGM. 
 
If a shareholder votes more than its eligible holding (for example, because some of its shares are disenfranchised 
pursuant to an Affected Share Notice), Equiniti shall use its reasonable endeavours to contact the relevant shareholder 
to resolve any discrepancies, however, to the extent Equiniti is unable to resolve such discrepancies by 10.00 a.m. on 
Tuesday, 11 February 2025, Equiniti will scale back the relevant shareholder's votes on a pro rata basis so that such 
shareholder's votes do not exceed those it is entitled to vote. 
Board changes 
As previously announced Jan De Raeymaeker will be joining the Board as Chief Financial Officer on 20 January 2025, 
replacing Kenton Jarvis who has succeeded Johan Lundgren as Chief Executive, and Julie Chakraverty will be joining the 
Board as a Non-Executive Director on 27 January 2025. Resolutions relating to Jan and Julie's election are therefore 
included in the business of the meeting. 
 
Moni Mannings OBE will not be putting herself forward for re-election and will therefore be stepping down at the 
conclusion of the AGM. Sue Clark will succeed Moni as Chair of the Remuneration Committee at that time. In addition the 
following changes will be made to the membership of the Committees at the conclusion of the AGM: 
   -- Ryanne van der Eijk will become a member of the Remuneration Committee. 
   -- Harald Eisenächer will become a member of the Safety & Operational Readiness Committee. 
 
The full membership of the Board Committees from the date of the AGM will therefore be as follows: 
   -- Audit Committee: David Robbie (Chair), Sue Clark, Catherine Bradley, Dr Detlef Trefzger. 
   -- Remuneration Committee: Sue Clark (Chair), Ryanne van der Eijk, Harald Eisenächer, David Robbie. 
   -- Nominations Committee: Stephen Hester (Chair), Sue Clark, Catherine Bradley, David Robbie, Dr Detlef 
  Trefzger. 
   -- Safety & Operational Readiness Committee: Dr Detlef Trefzger (Chair), Sue Clark, Julie Chakraverty, 
  Ryanne van der Eijk, Harald Eisenächer 
   -- Finance Committee: Catherine Bradley (Chair), Julie Chakraverty, Harald Eisenächer, David Robbie. 
 
 
 
In case of queries please contact: 
Institutional investors and analysts 
Adrian Talbot Investor Relations +44 (0)7971 592 373 

Media

Anna Knowles Corporate Communications +44 (0)7985 873 313 
Harry Cameron Teneo           +44 (0)20 7353 4200 
Olivia Peters Teneo           +44 (0)20 7353 4200 

LEI: 2138001S47XKWIB7TH90

----------------------------------------------------------------------------------------------------------------------- Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

ISIN:      GB00B7KR2P84 
Category Code: NOA 
TIDM:      EZJ 
LEI Code:    2138001S47XKWIB7TH90 
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State 
Sequence No.:  370221 
EQS News ID:  2066491 
 
End of Announcement EQS News Service 
=------------------------------------------------------------------------------------
 

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2066491&application_name=news&site_id=dow_jones%7e%7e%7ef1066a31-ca00-4e1a-b0a4-374bd7d0face

(END) Dow Jones Newswires

January 13, 2025 05:33 ET (10:33 GMT)

© 2025 Dow Jones News
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.